Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock & Full Exercise of Underwriters’ Option to ...
January 20 2021 - 7:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a
clinical-stage biotechnology company focused on the development of
novel therapies with the potential to improve the lives of patients
with immune-mediated diseases, today announced the closing of its
underwritten public offering of 7,868,421 shares of its common
stock at a public offering price of $9.50 per share, including
1,026,315 additional shares of common stock sold pursuant to the
full exercise of the underwriters’ option to purchase additional
shares. All of the shares in the offering were sold by Aldeyra. The
gross proceeds to Aldeyra following the underwriters’ exercise of
their option to purchase additional shares, before deducting
underwriting discounts and commissions and offering expenses, were
approximately $74.7 million.
Aldeyra anticipates using the net proceeds from the underwritten
offering for the continued development of its lead compound,
reproxalap, and its other product candidates, as well as for
working capital, and other general corporate purposes.
Jefferies LLC and SVB Leerink LLC acted as joint book-running
managers for the offering. BTIG LLC and Oppenheimer & Co. Inc.
acted as co-lead managers for the offering.
The shares of common stock described above were offered by
Aldeyra pursuant to a shelf registration statement on Form S-3
previously filed with the Securities and Exchange Commission (SEC)
and declared effective by the SEC on July 27, 2018. A final
prospectus supplement relating to and describing the terms of the
offering was filed with the SEC on January 14, 2021, and is
available on the SEC’s web site at www.sec.gov. Copies of the final
prospectus supplement and accompanying prospectus relating to these
securities may also be obtained by sending a request to: Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, New York 10022, by telephone at
877-821-7388 or by email at Prospectus_Department@Jefferies.com, or
from SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, Massachusetts 02110, by telephone at
1-800-808-7525, ext. 6132, or by email at
syndicate@svbleerink.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of these securities, nor will
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdictions.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a clinical-stage biotechnology company
focused on the development of novel therapies with the potential to
improve the lives of patients with immune-mediated diseases. Two of
the company’s lead investigational compounds, reproxalap and
ADX-629, target RASP (reactive aldehyde species), which are
elevated in ocular and systemic inflammatory disease and result in
cytokine release via activation of a broad array of inflammatory
factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Reproxalap is being evaluated in Phase 3 clinical trials in
patients with dry eye disease and allergic conjunctivitis. The
company’s clinical pipeline also includes ADX-2191, a dihydrofolate
reductase inhibitor in Phase 3 testing for proliferative
vitreoretinopathy, and ADX-1612, a chaperome inhibitor in
development for COVID-19 and ovarian cancer.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, including but not limited to statements regarding the
anticipated use of the proceeds from Aldeyra’s public offering of
common stock. These forward-looking statements are subject to a
number of risks, including the risk factors set forth from time to
time in Aldeyra’s SEC filings, including but not limited to the
risks that are described in the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” sections of Aldeyra’s Annual Report on Form 10-K for
the year ended December 31, 2019 and Aldeyra’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2020 which are on
file with the SEC and available on the SEC's website at
www.sec.gov. In addition to the risks described above and in
Aldeyra’s other filings with the SEC, other unknown or
unpredictable factors also could affect Aldeyra’s results. No
forward-looking statements can be guaranteed and actual results may
differ materially from such statements. The information in this
release is provided only as of the date of this release, and
Aldeyra undertakes no obligation to update any forward-looking
statements contained in this release on account of new information,
future events, or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210120005151/en/
Corporate: David McMullin Aldeyra Therapeutics, Inc. Tel:
781-761-4904 ext. 218 dmcmullin@aldeyra.com Investors & Media:
Scott Solomon Sharon Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024